Literature DB >> 32580960

Aspirin in Primary Prevention of Cardiovascular Events.

Deepa Soodi1, Jeffrey J VanWormer2, Shereif H Rezkalla3.   

Abstract

Aspirin has demonstrated a clear benefit in secondary prevention of coronary syndrome, while aspirin's effect in primary prevention is unclear. This report will explore the role of aspirin as primary prevention for various vascular events. It strives to provide a clear guide for clinicians on whether or not to prescribe aspirin for their patients for primary prevention. Current guidelines and recent trials failed to show clear benefit against primary prevention, with risks outweighing benefits in moderate to high risk patients. A thoughtful discussion between patients and their doctors should be conducted before beginning aspirin use. More studies are needed to gain a better understanding of aspirin use in primary prevention.
© 2020 Marshfield Clinic.

Entities:  

Keywords:  Aspirin; Cardiovascular events; Prevention

Year:  2020        PMID: 32580960      PMCID: PMC7428211          DOI: 10.3121/cmr.2020.1548

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  32 in total

1.  Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials.

Authors:  Jeffrey S Berger; Maria C Roncaglioni; Fausto Avanzini; Ierta Pangrazzi; Gianni Tognoni; David L Brown
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

2.  Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.

Authors:  Yasuo Ikeda; Kazuyuki Shimada; Tamio Teramoto; Shinichiro Uchiyama; Tsutomu Yamazaki; Shinichi Oikawa; Masahiro Sugawara; Katsuyuki Ando; Mitsuru Murata; Kenji Yokoyama; Naoki Ishizuka
Journal:  JAMA       Date:  2014-12-17       Impact factor: 56.272

3.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

4.  Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.

Authors:  R G Hart; J L Halperin; R McBride; O Benavente; M Man-Son-Hing; R A Kronmal
Journal:  Arch Neurol       Date:  2000-03

5.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

6.  The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein.

Authors:  G J Roth; P W Majerus
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

7.  Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial.

Authors:  Hisao Ogawa; Masafumi Nakayama; Takeshi Morimoto; Shiro Uemura; Masao Kanauchi; Naofumi Doi; Hideaki Jinnouchi; Seigo Sugiyama; Yoshihiko Saito
Journal:  JAMA       Date:  2008-11-09       Impact factor: 56.272

8.  Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.

Authors:  John J McNeil; Mark R Nelson; Robyn L Woods; Jessica E Lockery; Rory Wolfe; Christopher M Reid; Brenda Kirpach; Raj C Shah; Diane G Ives; Elsdon Storey; Joanne Ryan; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Barbara Radziszewska; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

9.  Aspirin overutilization for the primary prevention of cardiovascular disease.

Authors:  Jeffrey J VanWormer; Aaron W Miller; Shereif H Rezkalla
Journal:  Clin Epidemiol       Date:  2014-12-01       Impact factor: 4.790

10.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease.

Authors:  Jill Belch; Angus MacCuish; Iain Campbell; Stuart Cobbe; Roy Taylor; Robin Prescott; Robert Lee; Jean Bancroft; Shirley MacEwan; James Shepherd; Peter Macfarlane; Andrew Morris; Roland Jung; Christopher Kelly; Alan Connacher; Norman Peden; Andrew Jamieson; David Matthews; Graeme Leese; John McKnight; Iain O'Brien; Colin Semple; John Petrie; Derek Gordon; Stuart Pringle; Ron MacWalter
Journal:  BMJ       Date:  2008-10-16
View more
  2 in total

1.  Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas.

Authors:  Anna Breiburg; Ware G Kuschner
Journal:  Clin Med Res       Date:  2021-02-05

2.  Author Response to "Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease and Colorectal Carcinomas".

Authors:  Deepa Soodi; Jeffrey J VanWormer; Shereif H Rezkalla
Journal:  Clin Med Res       Date:  2021-02-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.